Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observation of Humoral and Cellular Immune Response After Additional Vaccine Dose With Different COVID-19 Vaccines in ESKD Patients in Hemodialysis Therapy

NCT05142501 is registered in ClinicalTrials.gov with Fresenius Medical Care Deutschland GmbH as lead sponsor.

NCT NCT05142501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05142501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observation of Humoral and Cellular Immune Response After Additional Vaccine Dose With Different COVID-19 Vaccines in ESKD Patients in Hemodialysis Therapy
Lead sponsor
Fresenius Medical Care Deutschland GmbH
Phase
Observational
Overall status
Terminated
Start date
April 25, 2022
Completion date
September 2, 2022
Enrollment
23 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases, covid-19, hemodialysis